<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748108</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/275/18</org_study_id>
    <nct_id>NCT03748108</nct_id>
  </id_info>
  <brief_title>Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy</brief_title>
  <official_title>A Randomized Clinical Trial Estimating the Efficacy of Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy to Decrease Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study to evaluate whether a bolus administration of intravenous
      lidocaine decreases postoperative pain and represents an opioid-minimizing strategy after
      abdominal hysterectomy compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total abdominal hysterectomy (TAH) is the most common gynecological operation worldwide. Some
      studies noticed about abused of opioids in postoperative care, led to a more adverse effect
      of opioids, slow recovery, prolong the length of hospitalized stay and consequently increase
      the unnecessary cost of treatment.

      Guidelines have considered using preoperative analgesics for reducing post-operative opioids
      consumption, including lidocaine infusion. With its anti-inflammatory, anti-hyperalgesia and
      analgesic properties, intravenous perioperative lidocaine infusion (IVLI) has been used for
      optimal postoperative care in different surgeries and in various procedures involving
      hysterectomy.

      Therefore, the aim of this study is to assess the efficacy of bolus administration of
      intravenous lidocaine at the time of abdominal hysterectomy to decrease postoperative pain
      and reducing morphine requirements, after TAH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be a single-center, randomized double-blind, placebo-controlled, parallel group trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participating patients, surgeons, anesthesiologists and medical investigators who will be involved in the data collection will be all blinded to the patient's group assignment until the collection of data for all cases will be complete.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog score during movement</measure>
    <time_frame>30 minutes postoperative</time_frame>
    <description>movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog score during rest</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>ranging from 0 to 10, where 0 no pain and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients need Fentanyl consumption</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>number of patients need Fentanyl consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days patients stay in hospital</measure>
    <time_frame>4 weeks</time_frame>
    <description>calculation of number of days patients stay in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Abdominal Hysterectomy</condition>
  <arm_group>
    <arm_group_label>lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.</description>
    <arm_group_label>lidocaine</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ranging age between 35-60 years a who undergoing elective total abdominal
             hysterectomy

        Exclusion Criteria:

          -  Participants had known sensitivity to lidocaine

          -  Participants had difficulty in intubation

          -  Participants were on chronic pain medication or already on long-term opioids

          -  Participants smokers

          -  Participants with disabilities who were unable to communicate pain levels

          -  refuse to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women undergoing abdominal hysterectomy</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f sallam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f sallam</last_name>
    <phone>01022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aswan University</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany f sallam, md</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, m</last_name>
      <phone>1019240504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>Postoperative Pain</keyword>
  <keyword>hysterectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

